Pharma Marketletter - UPDATE: Allos Therapeutics' brain cancer trial misses pri
Posted on Monday, April 28 @ 07:00:00 CDT by admin
April 28, 2003 -- Allos Therapeutics of the USA has reported disappointing preliminary results from its pivotal Phase III trial of the radiation sensitizer agent RSR13 (efaproxiral) in patients with brain metast
Click Here to read the entire article...
|
| |
|